| Total | No-MACCE | MACCE | P value |
---|---|---|---|---|
(n = 1694) | (n = 1594) | (n = 100) | ||
Age (y) | 57.8 ± 9.7 | 57.7 ± 9.7 | 59 ± 9.8 | 0.182 |
Sex, male | 1339 (79.0) | 1261 (79.1) | 78 (78.0) | 0.792 |
BMI, kg/m2 | 26 ± 3.1 | 26 ± 3.1 | 26.4 ± 3.3 | 0.181 |
Risk factors, n (%) | ||||
 Hypertension | 1025 (60.5) | 961 (60.3) | 64 (64.0) | 0.461 |
 Dyslipidemia | 958 (56.6) | 895 (56.1) | 63 (63.0) | 0.180 |
 Diabetes mellitus | 618 (36.5) | 566 (35.5) | 52 (52.0) | 0.001 |
 Current smoker | 489 (28.9) | 453 (28.4) | 36 (36.0) | 0.105 |
Medical history, n (%) | ||||
 Prior MI | 229 (13.5) | 204 (12.8) | 25 (25.0) | 0.001 |
 Prior PCI | 261 (15.4) | 236 (14.8) | 25 (25.0) | 0.006 |
 Prior CABG | 23 (1.4) | 18 (1.1) | 5 (5.0) | 0.001 |
 Prior stroke | 104 (6.1) | 97 (6.1) | 7 (7.0) | 0.712 |
 PAD | 30 (1.8) | 28 (1.8) | 2 (2.0) | 1.000 |
 CKD | 17 (1.0) | 16 (1.0) | 1 (1.0) | 1.000 |
 ACS type, n (%) |  |  |  | 0.954 |
 STEMI | 327 (19.3) | 309 (19.4) | 18 (18.0) |  |
 NSTEMI | 253 (14.9) | 237 (14.9) | 16 (16.0) |  |
 Unstable angina | 1114 (65.8) | 1049 (65.8) | 65 (65.0) |  |
Procedure characteristics | ||||
 Lesion vessel number | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) | 0.139 |
 Lesion complexity, n (%) | ||||
 Left main lesion | 141 (8.3) | 137 (8.6) | 4 (4.0) | 0.107 |
 Bifurcation lesion | 181 (10.7) | 169 (10.6) | 12 (12.0) | 0.661 |
 CTO | 289 (17.1) | 268 (16.8) | 21 (21.0) | 0.280 |
 Target vessel territory, n (%) | ||||
 Left main | 96 (5.7) | 95 (6.0) | 1 (1.0) | 0.037 |
 LAD | 1012 (59.7) | 962 (60.3) | 50 (50.0) | 0.041 |
 LCX | 466 (27.5) | 435 (27.3) | 31 (31.0) | 0.420 |
 RCA | 564 (33.3) | 522 (32.7) | 42 (42.0) | 0.057 |
 Multivessel intervention, n (%) | 384 (22.7) | 364 (22.8) | 20 (20.0) | 0.511 |
 Stent number | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 1.5 (1.0, 3.0) | 0.417 |
 Mean stent diameter, mm | 3.0 ± 0.4 | 3.0 ± 0.4 | 2.9 ± 0.4 | 0.026 |
 Total stent length, mm | 35.0 (23.0, 58.0) | 35.0 (23.0, 58.0) | 36.0 (24.0, 63.5) | 0.577 |
Laboratory results | ||||
 Baseline LDL-C, mg/dL | 95.1 (73.9, 122.6) | 95.1 (74.3, 122.2) | 94.9 (76.8, 125.7) | 0.455 |
 Baseline HDL-C, mg/dL | 42.1 ± 9.7 | 42.2 ± 9.8 | 40.6 ± 9.2 | 0.114 |
 Baseline TC, mg/dL | 166.5 ± 42.9 | 166.5 ± 43.2 | 166.7 ± 39.3 | 0.955 |
 Baseline TG, mg/dL | 124.8 (89.4, 176.1) | 115.1 (85.9, 161.3) | 119.9 (92.9, 163.1) | 0.399 |
 Baseline FPG, mg/dL | 104.6 (93.8, 124.6) | 104.2 (93.6, 124.0) | 112.2 (97.7, 152.4) | 0.004 |
 Baseline HbA1c, % | 6.4 ± 1.3 | 6.4 ± 1.3 | 6.7 ± 1.3 | 0.010 |
 Baseline creatinine, μmol/L | 71.7 ± 16.6 | 71.7 ± 16.6 | 71.4 ± 15.7 | 0.865 |
 Baseline uric acid, μmol/L | 355.4 ± 86.9 | 355.6 ± 87.3 | 352.8 ± 80.1 | 0.752 |
 Baseline TyG index | 8.82 (8.45, 9.24) | 8.82 (8.44, 9.23) | 8.97 (8.59, 9.42) | 0.027 |
 Mean follow-up TyG index | 8.73 (8.42, 9.05) | 8.72 (8.40, 9.04) | 8.96 (8.55, 9.28) |  < 0.001 |
 TyG index-SD | 0.20 (0.12, 0.29) | 0.20 (0.12, 0.29) | 0.23 (0.15, 0.32) | 0.025 |
 LVEF, % | 61.4 ± 7.8 | 61.5 ± 7.8 | 60.5 ± 8.0 | 0.217 |
Medications at discharge, n (%) | ||||
 Aspirin | 1694 (100.0) | 1594 (100.0) | 100 (100.0) | NA |
  Ticagrelor | 1694 (100.0) | 1594 (100.0) | 100 (100.0) | NA |
 DAPT interruption in 12 months | 550 (32.5) | 516 (32.4) | 34 (34.0) | 0.736 |
 Statin | 1674 (98.8) | 1575 (98.8) | 99 (99.0) | 1.000 |
 Ezetimibe | 290 (17.1) | 273 (17.1) | 17 (17.0) | 0.974 |
 β-receptor blocker | 946 (55.8) | 879 (55.1) | 67 (67.0) | 0.021 |
 ACEI/ARB | 881 (52.0) | 822 (51.6) | 59 (59.0) | 0.149 |
 Calcium-channel antagonist | 430 (25.4) | 409 (25.7) | 21 (21.0) | 0.299 |
 Oral hypoglycemic agents | 379 (22.4) | 346 (21.7) | 33 (33.0) | 0.009 |
 Metformin | 181 (10.7) | 163 (10.2) | 18 (18.0) | 0.015 |
 Alpha-glucosidase inhibitor | 222(13.1) | 203 (12.7) | 19 (19.0) | 0.072 |
 Meglitinide | 83 (4.9) | 73 (4.6) | 10 (10) .0 | 0.028 |
 Sulfonylurea | 96 (5.7) | 88 (5.5) | 8 (8.0) | 0.298 |
 Thiazolidinediones | 14 (0.8) | 13 (0.8) | 1 (1.0) | 1.000 |
 DPP-4 inhibitor | 9 (0.5) | 9 (0.6) | 0 (0) | 1.000 |
 SGLT-2 inhibitors | 5 (0.3) | 5 (0.3) | 0 (0) | 1.000 |
  GLP-1 receptor agonist | 3 (0.2) | 3 (0.2) | 0 (0) | 1.000 |
 Insulin | 100(5.9) | 87 (5.5) | 13 (13.0) | 0.002 |